- Current report filing (8-K)

 

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):		April 16, 2012

Biolase Technology, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	000-19627	87-0442441
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
4 Cromwell, Irvine, California		92618
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code:		949-361-1200

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On April 16, 2012, Biolase Technology, Inc. (the "Company") issued a press release announcing preliminary financial results for the first quarter ended March 31, 2012.

A copy of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On April 16, 2012, the Company issued a press release announcing the completion of its purchase of certain laser systems from Henry Schein, Inc.

A copy of the Company's press release is filed as Exhibit 99.2 to this Current Report on Form 8-K, and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

99.1 Press Release of Biolase Technology, Inc., dated April 16, 2012.
99.2 Press Release of Biolase Technology, Inc., dated April 16, 2012.

This Current Report on Form 8-K and the information contained in the press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K and the press release is not incorporated by reference into any filings of the Company, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless explicitly incorporated by specific reference into such filing.

---

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Biolase Technology, Inc.
April 16, 2012		By:		/s/ Federico Pignatelli
				Name: Federico Pignatelli
				Title: Chairman and Chief Executive Officer

---

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release of Biolase Technology, Inc., dated April 16, 2012.
99.2		Press Release of Biolase Technology, Inc., dated April 16, 2012.